Comparative Pharmacology
Head-to-head clinical analysis: NALFON versus RIMADYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NALFON versus RIMADYL.
NALFON vs RIMADYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fenoprofen, a propionic acid derivative, nonselectively inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis.
Selective cyclooxygenase-2 (COX-2) inhibitor, reducing prostaglandin synthesis involved in inflammation, pain, and fever.
NALFON (fenoprofen) 200-600 mg orally 3-4 times daily; maximum dose 3200 mg/day.
50-100 mg orally twice daily, or 100-200 mg rectally once daily (suppository).
None Documented
None Documented
3-4 hours (terminal half-life in healthy adults; prolonged in elderly and hepatic impairment).
Terminal elimination half-life: 12–18 hours in dogs at recommended doses. Clinical context: Supports twice-daily dosing; longer half-life in some breeds may require dose adjustment.
Renal: 90% (mostly as glucuronide conjugates and unchanged drug; unchanged drug ~1-5%); Fecal: <5%; Biliary: negligible.
Primarily hepatic metabolism (oxidation, conjugation) with ~70% of metabolites excreted in urine and ~30% in feces via biliary elimination. Less than 5% excreted unchanged.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)